Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1206598 | 1.00 | ALDH1A1 (1.00) | ALDH1A1GAAMEN1KMT2ALMNA | |
| SCHEMBL22367100 | 0.88 | ALDH1A1 (0.78) | ALDH1A1GAAMEN1KMT2ALMNA | |
| SCHEMBL30423425 | 0.87 | ALDH1A1 (0.76) | ALDH1A1GAAMEN1KMT2ALMNA | |
| SCHEMBL31058805 | 0.87 | ALDH1A1 (0.76) | ALDH1A1GAAMEN1KMT2ALMNA | |
| SCHEMBL7747580 | 0.85 | ALDH1A1 (0.74) | ALDH1A1GAAMEN1KMT2ALMNA | |
| SCHEMBL7747583 | 0.85 | ALDH1A1 (0.74) | ALDH1A1GAAMEN1KMT2ALMNA | |
| SCHEMBL4094186 | 0.83 | ALDH1A1 (0.71) | ALDH1A1GAAMEN1KMT2ALMNA | |
| SCHEMBL4094181 | 0.83 | ALDH1A1 (0.71) | ALDH1A1GAAMEN1KMT2ALMNA | |
| SCHEMBL4094184 | 0.83 | ALDH1A1 (0.71) | ALDH1A1GAAMEN1KMT2ALMNA | |
| SCHEMBL16503657 | 0.83 | ALDH1A1 (0.71) | ALDH1A1GAAMEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110039847-A1 | AMIDE DERIVATIVES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC (US) | 2011-02-17 | — | — | US | disclosed |
| EP-2215066-A1 | AMIDE DERIVATIVES AS SIRTUIN MODULATORS | Sirtris Pharmaceuticals, Inc. (US) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009058348-A1 | AMIDE DERIVATIVES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039847-A1 | AMIDE DERIVATIVES AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | ALDH1A1 871/4885GAA 752/4885MEN1 4415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.